Tubize-Fin
Financière de Tubize SA operates as a mono holding company whose sole investment is a stake in UCB which is a biopharma company in Belgium. It engages in discovering and developing treatments for patients suffering from serious illnesses that affects immune system or central nervous system. The company was incorporated in 1928 and is based in Brussels, Belgium.
Tubize-Fin - Asset Resilience Ratio
Tubize-Fin (TUB) has an Asset Resilience Ratio of 0.05% as of June 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2002–2021)
This chart shows how Tubize-Fin's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Tubize-Fin's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €1.00 Million | 0.05% |
| Total Liquid Assets | €1.00 Million | 0.05% |
Asset Resilience Insights
- Limited Liquidity: Tubize-Fin maintains only 0.05% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Tubize-Fin Industry Peers by Asset Resilience Ratio
Compare Tubize-Fin's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
ESSA Pharma Inc
NASDAQ:EPIX |
Biotechnology | 21.42% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Tubize-Fin (2002–2021)
The table below shows the annual Asset Resilience Ratio data for Tubize-Fin.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2021-12-31 | 46.17% | €1.51 Billion | €3.27 Billion | +43.14pp |
| 2013-12-31 | 3.03% | €54.65 Million | €1.80 Billion | +2.43pp |
| 2004-12-31 | 0.60% | €4.30 Million | €715.25 Million | +0.54pp |
| 2003-12-31 | 0.06% | €500.00K | €791.03 Million | -0.01pp |
| 2002-12-31 | 0.07% | €530.00K | €748.11 Million | -- |